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Effects of Atomoxetine on Growth in Children with
Attention-Deficit/Hyperactivity Disorder Following up
to Five Years of Treatment
Thomas J. Spencer, M.D.,1 Christopher J. Kratochvil, M.D.,2 R. Bart Sangal, M.D.,3
Keith E. Saylor, Ph.D.,4 Charles E. Bailey, M.D.,5 David W. Dunn, M.D.,6
Daniel A. Geller, M.B.B.S.,1 Charles D. Casat, M.D.,7 Robert S. Lipetz, D.O.,8
Rakesh Jain, M.D.,9 Jeffrey H. Newcorn, M.D.,10 Dustin D. Ruff, Ph.D.,11
Peter D. Feldman, Ph.D.,11 Amanda J. Furr, B.Sc.,6 and Albert J. Allen, M.D., Ph.D.11

ABSTRACT
Objective: To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year
study of the efficacy and safety of treatment with atomoxetine.
Methods: North American patients, 6–17 years old at study entry (N 5 1,312) and with Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ADHD, were studied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years.
Results: After 1 month’s treatment, patients weighed less than expected from their starting
percentiles relative to population norms, with a maximum shortfall at 15 months and a return
to expected weight by 36 months. Patients were slightly shorter than expected after 12 months,
reaching a maximum shortfall at 18 months and returning to expected height by 24 months.
Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the
third quartile for height, showed 5-year decreases from expected values. Those below median
height at baseline showed increases relative to expected values.
Conclusions: These interim results indicate that continuous atomoxetine treatment for up
to 5 years has little or no long-term effect on juvenile growth and final stature for most patients, although persistent decreases from expected may occur in some patients who are larger
than average before treatment.
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INTRODUCTION

A

TTENTION-DEFICIT/HYPERACTIVITY

DISORDER

(ADHD) is one of the most common psychiatric disorders in childhood, with an incidence rate estimated at between 3% and 7%
(American Psychiatric Association 2000) in the
United States and similar rates found in other
regions of the world (Wang et al. 1993; Andres
Carrasco et al. 1995). In many patients, the disorder persists through adolescence and into
adulthood, requiring chronic treatment over
many years. Pharmacotherapy for ADHD has
relied for several decades on the psychostimulants, particularly dextroamphetamine and
methylphenidate (MPH), but the range of
choices of medication has been considerably
expanded with the introduction of a nonstimulant treatment, atomoxetine.
Studies conducted with both the psychostimulants and atomoxetine indicate that, at
least acutely, treatments for ADHD among
children and adolescents are associated with
significant suppression of growth in height and
weight (Safer et al. 1972; Michelson et al. 2001;
Sund and Zeiner 2002; MTA Cooperative
Group 2004; Spencer et al. 2005). However, few
studies have been carried out past the 2-year
time point, and the long-term effects on growth
of treatment for ADHD are still unclear. To address this gap, we sought to examine the effects
of continuous atomoxetine treatment on height
and weight among children and adolescents
with ADHD over a span of up to 5 years, testing the hypothesis that suppression of growth
in height and weight is a temporary phenomenon. The 2-year interim results have been published previously (Spencer et al. 2005).
METHODS
Patient sample and study design
Recently, we analyzed the first set of 5-year
data from an ongoing 5-year longitudinal study
of the efficacy, safety, and tolerability of longterm treatment with atomoxetine. The data set
includes all patients from previous Lilly clinical trials of atomoxetine (13 studies: 6 placebocontrolled, 7 open-label) who entered open-label atomoxetine treatment. This report presents

the data on patients’ weight, height, and body
mass index (BMI). Patients were children and
adolescents 6–17 years of age at the time of initial study enrollment, either male or female,
weighing at least 20 kg at baseline, and had
been diagnosed with ADHD, as defined in the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association 1994), and confirmed with
the Schedule for Affective Disorders and Schizophrenia for School-age Children, Present and
Lifetime Version (K-SADS-PL; Kaufman et al.
1996). The drug development program allowed
patients who entered and completed a shortterm study the option of continuing treatment
in an extension study for a total exposure of up
to 5 years. Pre-extension trials ranged from 6
to 96 weeks in duration and used similar dose
ranges, with a starting dose of 0.5 mg/kg per
day, a target dose of 1.2 mg/kg per day, and a
maximum dose of up to 1.8 mg/kg per day in
most studies. Atomoxetine was administered
either once daily (3 studies) or as a divided
twice-daily dose (10 studies). Dosing during
the extension phase represented a continuation
of the treatment received during the acute
phase. If at any time a patient or investigator
felt that the patient was not obtaining sufficient
clinical benefit from treatment, participation
could be terminated.
In addition to the DSM-IV and K-SADS-PL
diagnostic entry criteria, initial criteria required
symptom severity to be at least 1.5 standard deviations (SD) above age and sex norms in 6 of
the 13 studies, and at least 1.0 SD above norms
in three of the studies, as assessed with the Attention-Deficit/Hyperactivity Disorder Rating
Scale-IV–Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv;
DuPaul et al. 1998; Faries et al. 2001). Patients
of any diagnostic subtype of ADHD were eligible to participate. Exclusion criteria included
serious medical illness, mental retardation, abnormal baseline laboratory values, abnormal
baseline electrocardiograms, organic brain disorders, a history of psychosis or bipolar disorder, alcohol or drug abuse within the past 3
months, and ongoing use of psychoactive medication other than the study drug. Patients were
recruited by referral and by advertisement. The
studies were approved at each site by an Insti-
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tutional Review Board and were conducted in
accordance with the ethical standards of the
1975 Declaration of Helsinki, as revised in 2000
(World Medical Association 2000). Parents and
guardians signed consent forms, and assent
was given by patients before enrollment.
Assessments and statistical methods
A portion of patients received only placebo
treatment during the pre-extension treatment
period and were therefore exposed to atomoxetine for the first time during the extension phase.
Accordingly, time zero for this analysis was defined as the time at which a patient began receiving atomoxetine, whether in the pre-extension trial or in the extension phase. Weight was
measured at every visit in each trial, and height
was measured at the initial and final study visits of the initial trial and at regular intervals not
to exceed 6 months during the extension phase.
Mean observed values and changes from baseline of weight, height, and BMI were obtained
and expressed as a percentile and corresponding z-score relative to population normative values for age and sex using the most current norms
from the National Center for Health Statistics
(NCHS) (Kuczmarski et al. 2000). Significance of
changes from baseline was assessed with Student’s t-test and Wilcoxon’s signed rank test. Extreme cases of difference from expected weight
or height were identified from patients’ baseline-to-end point change z-scores, with extreme
cases identified by a change z-score below 21.96
or above 11.96, a threshold equivalent to the
limits of a two-tailed 95% confidence interval.
Longitudinal models such as the mixed-model
repeated measures analysis of variance were
used to assess changes over time. Dose effects
were examined using a regression model for
change in weight, height, or BMI z-score versus
modal dose. Categorical data were assessed
with Fisher’s exact test. All tests were conducted
using a two-sided significance level of 0.05.

RESULTS
Patient sample
A total of 1,312 patients entered the longterm study. As indicated in Table 1, the major-

TABLE 1. PATIENT DEMOGRAPHICS
BASELINE CHARACTERISTICS
Characteristic
Sex, n (%)
Female
Male
Racial origin, n (%)
African American
Caucasian
East Asian
Hispanic
Other
Age at entry, years
Mean (SD)
Range
ADHD Subtype, n (%)
Combined
Hyperactive/Impulsive
Inattentive
Prev. Stim. Exp., n (%)

All patients
(N 5 1,312)

AND

5-year patients
(N 5 61)

308 (23.5)
1,004 (76.5)

13 (21.3)
48 (78.7)

95
1,084
9
75
49

3
53
0
3
2

(7.2)
(82.6)
(0.7)
(5.7)
(3.7)

11.0 (2.5)
6.1–18.0
849
38
370
881

(64.8)
(2.9)
(28.2)
(67.8)

(4.9)
(86.9)
(0.0)
(4.9)
(3.3)

10.2 (1.7)
6.2–13.4
51
1
9
39

(83.6)
(1.6)
(14.8)
(63.9)

SD 5 Standard deviation; ADHD 5 attention-deficit/
hyperactivity disorder; Prev. Stim. Exp. 5 previous
exposure to stimulants.

ity (76.5%) were boys, with a mean age at first
exposure to atomoxetine of 11.0 years (SD 5
2.5). Most (82.6%) were of Caucasian origin.
The most prevalent diagnostic category among
the 1,257 patients providing data was ADHD
of the combined type (64.8%), while 28.2% were
predominantly inattentive and 2.9% were predominantly hyperactive–impulsive. The final
mean dose of atomoxetine was 1.46 mg/kg per
day (SD 5 0.53). Sixty one patients to date have
reached the 5-year time point. This report will
focus on their longitudinal data set, as it is the
most complete. Demographics and baseline
characteristics for the 5-year subsample were
not appreciably different from those of the
overall study sample (Table 1), although proportionally fewer patients diagnosed with the
predominantly inattentive subtype of ADHD
have reached the 5-year time point than have
entered the study initially. To date, 384 patients
(29.3%) remain enrolled in the study, having
not yet reached the 5-year time point. Another
926 (70.6%) have discontinued. The most frequent reason for discontinuation to date has
been Personal Conflict/Other (25.4%), followed by Loss to Follow-up (16.5%). Lack of
Efficacy accounts for 16.3%, while Adverse
Event accounts for 5.3%. Of the latter, only 1
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patient (0.1%) cited weight loss and 2 (0.2%)
cited decreased appetite as the adverse event
leading to discontinuation.
Weight results
At baseline, the observed-case mean weight
for the subsample of patients who have stayed
in the study and to date have reached 5 years of
therapy was 40.2 kg (SD 5 13.0), or 88.4 lb (SD 5
28.6), corresponding to a mean weight percentile
of 67.8 (Table 2), well above the NCHS median.
After 1 month of treatment, a significant decrement was seen relative to the expected weight
(Fig. 1A), with patients falling to the 66.2 percentile (observed-case mean change from baseline: 21.6 percentage points, SD 5 3.5, n 5 61,
p , 0.001). A maximum decrement from expected was reached at the 15th month of treatment, with patients falling to the 57.9 percentile
(mean change: 29.9 percentage points, SD 5
14.2, p , 0.001). By the 36th month, the weight
was no longer significantly different from expected, with patients’ weight having risen to the
65.4 percentile (mean change: 23.1 percentage
points, SD 5 19.9, p 5 0.12), and by the 5-year
time point, patients had slightly overshot their
starting weight percentile, although not significantly so, rising to the 70.5 percentile (mean
TABLE 2.

Measure
Weight
(n 5 61)

Height
(n 5 53)

BMI
(n 5 52)

CHANGES

IN

WEIGHT, HEIGHT,

AND

change: 12.6 percentage points, SD 5 22.8,
p 5 0.75). The last-observation-carried-forward
mean weight difference from expected at 5
years, based on the starting percentile and extrapolating from the growth norms for age- and
sex-matched controls, rather than from the percentile alone, was an increase relative to baseline of 11.1 kg (SD 5 12.7), or 2.4 lb (SD 5 27.9),
representing a statistically nonsignificant increase from the starting percentile of 1.1 points
(SD 5 22.4, p 5 0.70). No extreme cases of a
shortfall from predicted weight were found, and
one case of extreme gain was seen, with a patient starting the study with a height z-score of
20.61, equivalent to a percentile score of 26.9,
and completing with a z-score of 12.10, equivalent to a percentile score of 93.1, an increase of
48.6 kg (106.9 lb) over the 5-years of the study,
rather than the 27.6 kg (60.7 lb) that was expected for this patient. Examination of the overall sample revealed no effects of modal dose on
changes in weight z-score (r 2 , 0.001, p 5 0.85).
When patients who had reached the 5-year
time point were stratified on the basis of their
starting weight quartile, a pattern of differential growth in weight was observed over the 5year observation period (Table 3). The greatest
gains were seen in the patients who were lightest at study entry. Patients with weight per-

BODY MASS INDEX

FROM

BASELINE

Value

Baseline:
mean (SD)

5-Year
time point:
mean (SD)

Actual (kg)
Predicted (kg)
Actual (lb)
Predicted (lb)
z-scorea
Percentile
Actual (cm)
Predicted (cm)
Actual (in)
Predicted (in)
z-scorea
Percentile
Actual
Predicted
z-scorea
Percentile

40.2 (13.0)
—
88.4 (28.6)
—
0.72 (1.07)
67.8 (28.1)
139.9 (11.7)
—
55.1 (4.6)
—
0.23 (1.00)
55.7 (28.9)
19.5 (3.8)
—
0.73 (1.01)
70.3 (25.8)

70.0
68.9
153.9
151.5
0.77
68.9
170.0
169.7
66.9
66.8
0.27
57.9
24.1
24.0
0.70
68.1

(20.0)
(17.1)
(44.0)
(37.7)
(1.09)
(27.4)
(9.6)
(9.3)
(3.8)
(3.6)
(1.01)
(29.6)
(5.6)
(5.0)
(1.09)
(28.4)

TO THE

FIVE-YEAR TIME POINT

Change:
mean (SD)
129.8
128.7
166.5
163.1
10.05
11.1
130.1
129.8
111.9
111.7
10.04
12.1
14.5
14.4
20.03
22.2

(13.3)
(7.6)
(29.3)
(16.8)
(0.79)
(22.4)
(8.2)
(6.9)
(3.2)
(2.7)
(0.75)
(23.6)
(3.5)
(1.6)
(0.83)
(24.1)

p value
,0.001
,0.001
.—
.—
0.62
0.70
,0.001
,0.001
.—
.—
0.71
0.52
,0.001
,0.001
0.82
0.52

SD 5 Standard deviation; BMI 5 body mass index; kg 5 kilogram; lb 5 pound; cm 5 centimeter; in 5 inch.
az-Scores are standard scores that indicate how far, and in what direction, an item deviates from its distribution’s
mean, expressed in units of its distribution’s standard deviation.

693

ATOMOXETINE AND LONG-TERM GROWTH

A

B

FIG. 1. Mean percentile weight (A) and height (B) as a function of time of exposure to atomoxetine. Data include
all patients with a baseline measurement and a measurement at or after the 5-year time point. The dashed lines indicate the baseline percentiles. The number of patients at each data point varies between 53 and 61 for the weight
curve, and between 51 and 53 for the height curve, due to the fact that not all patients provided both sets of data at
each time point. ap , 0.05, relative to baseline percentile; bp , 0.001, relative to baseline percentile.

centiles that fell into successively higher quartiles at baseline showed successively smaller increases in weight percentile, with the heaviest
group at baseline in fact showing a significant
decrease in weight percentile at the 5-year time
point.
Height results
Observed-case mean height at baseline for
the patients to date who have reached the 5year time point was 139.9 cm (SD 5 11.7), or 4
TABLE 3.
FROM

Measure
Weight percentile

Height percentile

BMI percentile

feet 7 inches (SD 5 4.6 inches), corresponding
to a mean height percentile of 55.7 (Table 2),
slightly above the NCHS median. Twelve
months after initiation, a significant decrement
from expected height was apparent, with patients’ mean height percentiles falling to the
52.0 percentile (mean change from baseline:
23.4 percentage points, SD 5 10.8, n 5 45, p 5
0.022). A maximum decrement from expected
height was reached by the 18-month time point
(Fig. 1B), with patients’ mean height falling to
the 49.0 percentile (mean change: 26.6 per-

CHANGES IN WEIGHT, HEIGHT, AND BODY MASS INDEX PERCENTILE
BASELINE TO THE FIVE-YEAR TIME POINT, BY BASELINE QUARTILE

Baseline
percentile
range
0 to 25th
25th to 50th
50th to 75th
75th to 100th
0 to 25th
25th to 50th
50th to 75th
75th to 100th
0 to 25th
25th to 50th
50th to 75th
75th to 100th

n

Baseline:
mean (SD)

5-Year
time point:
mean (SD)

5
17
8
31
11
13
8
21
3
11
11
27

15.7
41.0
62.7
92.2
16.0
38.0
59.3
86.2
9.9
42.7
63.3
91.1

39.6
51.5
65.9
84.0
30.2
54.3
43.3
80.1
47.6
47.6
57.9
83.0

(6.6)
(7.2)
(8.4)
(7.2)
(7.3)
(6.0)
(8.2)
(6.6)
(12.9)
(6.4)
(6.0)
(7.0)

(30.4)
(24.9)
(22.3)
(19.5)
(24.7)
(25.7)
(15.1)
(21.6)
(44.2)
(24.2)
(28.6)
(19.9)

SD 5 Standard deviation; BMI 5 body mass index.
values were derived from paired t-tests to assess within-group differences.

ap

Change:
mean (SD)
123.8
110.4
13.2
28.2
114.1
116.3
215.9
26.1
137.7
15.0
25.5
28.2

(28.5)
(25.7)
(16.9)
(15.8)
(20.8)
(22.9)
(10.7)
(21.7)
(33.5)
(22.8)
(27.4)
(17.9)

p value
for group
differencesa
0.14
0.11
0.61
0.007
0.048
0.025
0.004
0.21
0.19
0.49
0.52
0.026
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centage points, SD 5 13.1, p , 0.001), but by 24
months, mean percentile was no longer significantly different from expected, with patients’
mean height rising slightly to the 49.7 percentile (mean change: 23.9 percentage points,
SD 5 15.2, p 5 0.09). By the 54th month, patients slightly overshot their starting percentile
(mean change: 10.2 percentage points, SD 5
24.5, p 5 0.99), and at 5 years, patients were at
the 58.8 percentile (mean change: 12.7 percentage points, SD 5 23.9, p 5 0.48). The lastobservation-carried-forward mean height difference from expected at 5 years, extrapolating
from the growth norms for age- and sexmatched controls, was 10.3 cm (SD 5 5.3), or
10.1 inches (SD 5 2.1 inches), a statistically
nonsignificant increase in percentile of 2.1
points (SD 5 23.6, p 5 0.517). One extreme case
of a decrement from predicted height was
found, with a patient starting the study with a
height z-score of 11.10, equivalent to a percentile score of 86.4, and completing with a zscore of 22.37, equivalent to a percentile score
of 10.30, in effect, a growth of just 4.5 cm (1.8
inches) over the 5-years of the study, rather
than the 19.8 cm (7.8 inches) that was expected
for this patient. No cases of extreme gain in
height were seen. Examination of the overall
sample revealed no effects of modal dose on
changes in height z-score (r2 , 0.001, p 5 0.89).
Stratified on the basis of starting height quartiles, patients reaching the 5-year time point
again showed differential growth patterns over
the 5-year observation period (Table 3). While
not exactly a graded pattern as for weight percentiles, patients in the lower two quartiles
showed significantly greater increases in height
relative to age and sex norms, with the shortest patients at baseline demonstrating the
largest mean increase in height percentile. Patients in the upper quartiles, by contrast,
showed decreases in height percentile from
baseline, with the greatest decrease, reaching
statistical significance, occurring in the third
quartile. These patients, on average, arrived at
the 5-year time point with a height that was in
fact below the median. The decrease in the
highest baseline quartile was considerably less,
and the difference from baseline did not
achieve statistical significance.

SPENCER ET AL.

BMI results
Observed-case mean BMI at baseline for patients reaching the 5-year time point (Table 2)
was 19.5 (SD 5 3.8), corresponding to a mean
BMI percentile of 70.3, nowhere near levels of
obesity, but again well above the norm for ageand sex-matched peers. By the 5-year time
point, patients’ mean BMI percentile had fallen
slightly to 68.1 (SD 5 28.4), a 2.2-point decrease
from baseline (p 5 0.52). No extreme cases of a
shortfall from predicted BMI were found, and
one case of extreme gain was seen, with a patient starting the study with a BMI z-score of
20.68, equivalent to a percentile score of 24.8,
and completing with a z-score of 12.05, equivalent to a percentile score of 91.5, an increase
in BMI from 15.2 at baseline to 24.7 at the 5year time point. This case involved a different
patient from those involved in the cases of extreme gain in weight or extreme decrement in
height. Examination of the overall sample revealed no effects of modal dose on changes in
BMI z-score (r2 , 0.001, p 5 0.94). Stratified by
starting BMI quartile, patients again showed a
graded pattern of growth over the 5-year observation period (Table 3), but the only statistically significant change in percentile occurred
in the patients with highest BMIs at baseline,
possibly reflecting the decrease in weight percentile among patients in the top quartile for
weight at baseline.
DISCUSSION
These results represent the largest data set to
date of patients studied for the effects of ADHD
treatment on growth over such an extended period. The findings indicate that there is a small,
temporary decrement in growth rate associated
with chronic use of atomoxetine in developing
children and adolescents. The decrement of
growth in weight was noticeable by the first
postbaseline time point after 1 month of continuous treatment, followed nearly a year later
by a very brief decrement of growth in height.
Mean actual height returned to expected values by the end of the second year of treatment,
and mean actual weight returned by the end of
the third year, indicating that any effects on de-
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velopment overall were neither persistent nor
irrecoverable. The timing of the decrement in
growth rates suggests that one possible mechanism is an effect of the medication on appetite.
Nausea and stomach pain are frequently reported during the early stages of treatment
with atomoxetine (Kratochvil et al. 2001;
Spencer et al. 2002), and it is possible that this
could have influenced patients’ desire to eat, as
has been seen in studies involving MPH
(Kramer et al. 2000). Alternatively, the putative
loss of appetite could have been due to a
temporary perturbation of the central noradrenergic systems involved in hunger or satiety (Wellman 2000), similar to the dopaminergic system-mediated appetite suppression
associated with the use of the stimulants (Freed
and Mizel 1952; Poindexter 1960). Alternatively, this treatment could have directly affected neuroendocrine systems involved with
growth mechanisms, also known to be under
catecholaminergic control, although this possibility is unlikely, given that disturbances of
hormonal levels have not been seen in previous studies with atomoxetine (Kratochvil et al.
2001; Spencer et al. 2002).
The reversibility of the growth deficits seen in
this study is reassuring, because it indicates that
atomoxetine is unlikely to have a permanent effect on growth and final stature. These findings
extend those in past studies with the compound.
This is particularly salient, because younger children may be the most affected by any potential
growth-suppressant effects of ADHD treatment
(Faraone et al. 2005a; Spencer et al. 1996; Zachor
et al. 2006), although this has not been a consistent finding (Schertz et al. 1996; Sund and Zeiner
2002). Kratochvil and colleagues (Kratochvil et
al. 2006) conducted a meta-analysis of 13 studies involving atomoxetine and showed that, in
young children (6–7-years old), the effects of atomoxetine on growth appeared to begin to reverse but were nevertheless still quite apparent
at the 2-year time point. By contrast, an analysis by Wilens et al. (Wilens et al. 2006) of adolescents with ADHD showed a complete reversal of any effect of atomoxetine on mean height
and weight by 2 years of treatment.
Underscoring these results is the finding that
children are more susceptible than adolescents

to treatment-emergent appetite suppression
and other gastrointestinal effects (Wilens et al.
2006). This supports the notion that the effects
of treatment on growth are felt more acutely
in younger patients. Charach and associates
(Charach et al. 2006) examined the effects of
psychostimulants on growth over a period of
up to 5 years in a small group of preadolescent
children. Their results suggest that a “small but
distinct risk” of a persistent decrement in
growth rate occurs with long-term use of stimulants, and that such risk increases with the
dose, particularly above recommended doses
(.2.0 mg/kg per day MPH-equivalents). Despite such findings, however, the persistence of
growth deficits beyond the second or third year
of treatment with psychostimulants appears
unlikely, as the predominance of evidence indicates that growth deficits tend to attenuate
by the end of the first or second year, with
growth rates returning toward expected levels
by the second or third year (Satterfield et al.
1979; Poulton and Cowell 2003; Faraone et al.
2005a; Spencer et al. 2006; Zachor et al. 2006).
When patients in the present study were
classified according the quartile of their starting weight, height, or BMI percentiles (relative
to norms), differences in patterns of growth
were seen, whereby the children who were
smallest at baseline showed the greatest increases in growth above expected, while those
who were largest at baseline showed the greatest decreases relative to expected. This pattern
was not uniform, however, for while patients
below the median for weight at baseline
showed considerable increases above their
predicted weight percentile at the 5-year time
point, the differences from predicted in fact
did not achieve statistical significance. Moreover, whereas patients below the median for
height at baseline showed significant increases
in height percentile over prediction, and those
in the third quartile (50 to 75 percentiles) persistently showed a significantly lower height
percentile from predicted, those in the top
quartile showed a height percentile at 5 years
that was not significantly different from predicted.
It is unclear whether these differential patterns of changes in growth reflect a true size-
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based difference of treatment on growth rates,
whether children were simply “normalizing”
in body size over time independently of treatment, or if this merely represents a form of statistical “regression to the mean.” A “normalizing” effect is an unlikely cause, because a
decrement was seen in the growth in height, as
well as in weight, while a simple regression to
the mean is also questionable, because the patterns of overshoot and undershoot from expected growth across size classes were not uniform, as, for example, the height decrement in
the third quartile (50th to 75th percentile) was
greater than the nonsignificant decrement in
the top quartile. Alternatively, patients who
were smaller at baseline may represent children with a later onset of puberty, and their
greater growth during treatment may simply
reflect a “catching up” in size with their peers.
Unfortunately, Tanner-stage data were not captured during these studies, so the current results do not address whether the patient sample showed a change in the tempo of puberty
relative to norms or whether the treatment had
an effect on maturation. The latter appears unlikely, however, as a previous atomoxetine
study (Michelson et al. 2004) that included an
assessment of Tanner stages has shown that the
treatment appears not to affect maturation or
its timing.
This putative differential size-based effect
of treatment on growth is consistent with the
results from past studies of treatments for
ADHD. Studies involving the psychostimulants (Schertz et al. 1996; Faraone et al. 2005a;
Zachor et al. 2006) have also revealed that children who are largest at baseline show the
greatest growth deficits, whereas those who
are smallest show the least effect. A common
finding, and one that contradicts the stereotype of the underweight, hyperkinetic child
with ADHD, is that children with ADHD in
clinical trials tend to be heavier than expected
from norms at baseline (Sund and Zeiner 2002;
Holtkamp et al. 2004; Faraone et al. 2005b;
Spencer et al. 2006). In fact, one theory suggests that there is a linkage between ADHD
and obesity through what has been referred to
as an “environmental oversampling disorder”
(Bazar et al. 2006), a phenomenon by which
an individual is predisposed to taking in an
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excess of environmentally supplied stimuli,
with ingestive behavior merely representing
one type of stimulus-seeking behavior. Other
analyses suggest that the prevalence of obesity
among children with ADHD may merely reflect that of the general population (Curtin
et al. 2005). During long-term treatment for
ADHD, weight among the heavier children appears to “normalize,” and a decrease is seen
over time in the proportion of overweight children. Nevertheless, deficits in weight, height,
and BMI did occur among patients in the
“lower quartiles as well, so considerable vigilance is still warranted in monitoring patients’
tolerance to treatment with respect to growth
deficits.
One point of interest in any study of changes
in growth pattern during pharmacological
treatment is whether any such effects are associated with the magnitude of the dose. In the
present study, we found no relation between
patients’ modal doses of atomoxetine and the
magnitude of the differences between their expected and actual growth. Similar findings have
also been obtained in most studies involving the
psychostimulants, because effects on growth
are typically seen over the entire range of doses
administered (Lisska and Rivkees 2003; Schertz
et al. 1996; Pliszka et al. 2006). This contrasts
with the findings by Charach et al. (Charach et
al. 2006), who found that only doses of psychostimulant above the equivalent of 1.5 mg/kg
per day of MPH were associated with a significant risk of a diminished growth rate for
weight, whereas doses above the equivalent of
2.5 mg/kg per day were associated with a significant risk of a decreased growth rate for
height. It should be noted, however, that the latter dose is at the upper end of the recommended
maximum dose for stimulants (2.0–2.5 mg/kg
per day), whereas the doses of atomoxetine
used in the present study were generally within
the recommended range.
Because this was a long-term study, one of its
limitations was the difficulty of maintaining patients in the study long enough to reach the 5year time point. Rates of discontinuation due to
an adverse event (5.3%) or lack of efficacy
(16.3%) were notably low, but the overall discontinuation rate (70.6%) was high, as expected
from a study of this length. Consequently, the
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sample size at the 5-year time point is less than
optimal, making it more difficult to conduct secondary analyses of subgroups with sufficient
statistical power. Moreover, the data taken at the
5-year time point represent a somewhat skewed
sample, because patients who were able to remain in the study for that length of time may
not be representative of those who were not.
This may be a minor point, however, as the overwhelming majority of discontinuations occurred
for reasons not related to tolerance or efficacy.
Also ameliorating this weakness to some extent
is the fact that this was a large study, with an
entering sample size of well over a thousand patients. Doses were well controlled and kept
within recommended guidelines, so that, while
the study sample may not represent a naturalistic and numerically defined cohort as in the
only other 5-year drug growth study to date,
conducted by Charach et al. (Charach et al.
2006), the present study avoids many of the limitations of that study, which was characterized
by incomplete descriptions of patient disposition and heterogeneous levels of exposure
within its defined dose ranges. Nevertheless,
another source of skewing arises from the nature of the North American ADHD patient population itself, which the sample reflects in consisting of a majority of males, Caucasians, and
patients of the combined diagnostic subtype.
Therefore, these findings may not generalize to
each ADHD patient, although the findings with
this sample should be still representative of the
overall U.S. patient population.
Due also to its long-term nature, this study
was conducted under nonrandomized, openlabel conditions, because it would have been
unethical to maintain a patient on placebo for
such a protracted period. This makes it difficult to discern whether observed changes or
differences from norms are due to the treatment or to the condition itself. The previous
discussion of obesity illustrates the confusion
that can be generated from the reliance on standard growth curves in the absence of a control
for the untreated disease state. The situation is
further complicated by the recalibration that
such standard curves have undergone, such
that the median weight they now describe is
more prescriptive than descriptive in nature.
Although the average weight in the population

has been increasing over time, average height
has remained stable. To avoid contributing to
the trend of increasing obesity in the United
States, the standards committee that constructed the most recent norms decided to use
the population statistic for weight from earlier
studies with lower mean absolute values. As a
result, the average relative weight in the population today is expected to be greater than the
50th percentile described by the growth curves
currently used as the norm.
In summary, these findings show that use of
atomoxetine among 6- to 18-year-olds is associated with a modest slowing of growth velocity over the initial 18 months, followed by a return to expected weights and heights by 2–3
years. Mean z-scores and percentiles for
weight, height, and BMI were not significantly
different from baseline from approximately the
3-year time point onward. However, analysis
by quartile showed that weight deficits persisted to the 5-year time point among patients
who were heaviest at baseline, and patients in
the top quartile at baseline showed a significant mean decrease in BMI. In contrast, patients
who were shortest at baseline showed a significant mean increase in height above expected.
These results suggest that, for most children
and adolescents with ADHD, atomoxetine
appears unlikely to have a persistent effect on
growth and final stature, although some
younger patients who are heavier or taller than
average may show persistent decreases from
expected weight or height over time.

DISCLOSURES
This work was sponsored by Eli Lilly and
Company. Dr. Spencer receives research support from Shire, Lilly, GlaxoSmithKline, Pfizer,
McNeil, Novartis, and the National Institute
of Mental Health (NIMH), is a member of
speaker’s bureaus for GlaxoSmithKline, Lilly,
Novartis, Wyeth, Shire, and McNeil, and serves
on advisory boards for Shire, Lilly, GlaxoSmithKline, Pfizer, McNeil, and Novartis. Dr.
Kratochvil is supported by NIMH Grant
5K23MH06612701A1, receives study drug for
an NIMH-funded study from Lilly, receives
grant support from Lilly, McNeil, Abbott,

698

and Cephalon, is a consultant for Lilly, Shire,
Cephalon, Organon, AstraZeneca, BoehringerIngelheim, Abbott, and Pfizer, and is a member
of the Lilly speaker’s bureau. Dr. Sangal has received research support within the past 5 years
from Lilly, GlaxoSmithKline, Cephalon, SanofiAventis, Somaxon, Merck, Organon, Novartis,
Takeda, and Pfizer. Dr. Saylor receives research/consultancy support from Lilly, BristolMyers Squibb, Shire, McNeil, New River, and
Otsuka. Dr. Bailey is a consultant, an advisory
board member, and on the speaker bureau for
Lilly, and has participated in research as an investigator with Lilly, McNeil, Novartis, Shire,
Bristol-Meyers Squibb, UCB, Cephalon, and
Sanofi-Aventis. Dr. Dunn receives grant support from Lilly, McNeil, Otsuka, and Psychogenics and is a speaker for Lilly and McNeil.
Dr. Geller receives/d research support from,
is/has been a speaker for, or is/has been on the
advisory board for the following: Shire, Lilly,
Pfizer, Bristol-Myers Squibb, Novartis, Forest,
and GlaxoSmithKline, and other sources of research support include: private foundations:
Obsessive Compulsive Foundation, Tourette
Syndrome Association, Wallace Foundation,
McIngvale Family Foundation, NIH: NIMH,
NINDS. Dr. Casat receives research grant support from AstraZeneca, Bristol-Myers Squibb,
Lilly, GlaxoSmithKline, Novartis, Sanofi-Aventis, and Shire, and serves on the speaker panel
for UCB and an advisory board for Lilly. Dr.
Lipetz has received research support from Lilly
and has served on their speaker panel and
advisory board. He has no other financial relationships with industry. Dr. Jain receives research grants from Lilly, Forest, GlaxoSmithKline, Merck, Pfizer, and Sepracore, serves as a
consultant for Lilly and as a speaker for GlaxoSmithKline, Pfizer, Wyeth, and Lilly. Dr. Newcorn receives grant support from Lilly, Novartis, Ortho-McNeil, and Shire, is a consultant to
Lilly, Novartis, Ortho-McNeil, and Shire, is
a speaker for Lilly, Novartis, Ortho-McNeil,
Shire, and Cephalon, and is a member of advisory boards at Lilly, Novartis, Ortho-McNeil,
Shire, and Cephalon. Drs. Ruff, Feldman, and
Allen are employees and shareholders of Lilly
and Company. Ms. Furr was supported as a
summer intern by Lilly and has no other financial relationships.

SPENCER ET AL.

ACKNOWLEDGMENT
The authors are grateful to Mr Kurt Baker for
his contributions to the statistical programming
of these analyses.
REFERENCES
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington (DC), American Psychiatric Association, 2000.
Andres Carrasco MA, Catala MA, Gomez-Beneyto M:
Study of the prevalence of the attention deficit hyperactivity disorder in ten-year-old children living in the
Valencia metropolitan area. Actas Luso Esp Neurol
Psiquiatr Cienc Afines 23:184–188, 1995.
Bazar KA, Yun AJ, Lee PY, Daniel SM, Doux JD: Obesity
and ADHD may represent different manifestations of
a common environmental oversampling syndrome: A
model for revealing mechanistic overlap among cognitive, metabolic, and inflammatory disorders. Med
Hypotheses 66:263–269, 2006.
Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R:
Stimulant treatment over 5 years: Effects on growth. J
Am Acad Child Adolesc Psychiatry 45:415–421, 2006.
Curtin C, Bandini LG, Perrin EC, Tybor DJ, Must A:
Prevalence of overweight in children and adolescents
with attention deficit hyperactivity disorder and
autism spectrum disorders: A chart review. BMC Pediatrics 5:48, 2005.
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD
Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, The Guilford Press, 1998.
Faraone SV, Biederman J, Monuteaux M, Spencer T: Longterm effects of extended-release mixed amphetamine
salts treatment for attention-deficit/hyperactivity disorder on growth. J Child Adolesc Psychopharmacol
15:191–202, 2005a.
Faraone SV, Biederman J, Spencer TJ, Michelson D, Adler LA,
Reimherr FW, Glatt SJ: Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: A drug-placebo response curve analysis. Behav Brain Funct 1:16, 2005b.
Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation
of the ADHD Rating Scale as a clinician administered
and scored instrument. J Atten Disord 5:39–47, 2001.
Freed SC, Mizel M: The use of amphetamine combinations for appetite suppression. Ann Int Med 36:1492–
1497, 1952.
Holtkamp K, Konrad K, Müller B, Heussen N, Herpertz
S, Herpertz-Dahlmann B, Hebebrand J: Overweight
and obesity in children with attention-deficit/hyperactivity disorder. Int J Obes 28:685–689, 2004.
Kaufman J, Birmaher B, Brent D, Rao U, Ryan N: KiddieSADS-Present and Lifetime Version (K-SADS-PL).
Pittsburgh, University of Pittsburgh Press, 1996.

ATOMOXETINE AND LONG-TERM GROWTH

699

Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S:
Predictors of adult height and weight in boys treated
with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 39:517–524,
2000.
Kratochvil CJ, Wernicke JF, Michelson D, Vaughan B, Bohac D, Harrington M, Baker N, May D, Burke WJ:
Long-term safety of atomoxetine in the treatment of
ADHD. Presented at The 48th Annual Meeting of the
American Academy of Child and Adolescent Psychiatry, October 23–28, 2001, Honolulu, HI, Abstract number P119.
Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD,
Feldman PD, Gelowitz DL: Effects of long-term atomoxetine treatment for young children with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919–927, 2006.
Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal
KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL: CDC growth charts: United States. Advance
data from vital and health statistics. Report Nr. 314.
Hyattsville (Maryland), National Center for Health Statistics, 2000.
Lisska MC, Rivkees SA: Daily methylphenidate use slows
the growth of children: A community based study. J
Pediatr Endocrinol Metab 16:711–718, 2003.
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K,
Sallee FR, Spencer T, Atomoxetine ADHD Study
Group: Atomoxetine in the treatment of children and
adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response
study. Pediatrics 108:e83, 2001.
Michelson D, Spencer T, Bangs M, Zhang S, Ruff D, Gao
H, Feldman P: Developmental outcomes of long-term
atomoxetine treatment in ADHD. Presented at The 51st
Annual Meeting of the American Academy of Child
and Adolescent Psychiatry, October 19–24, 2004; Washington, DC. Abstract number A2.
MTA Cooperative Group: National Institute of Mental
Health Multimodal Treatment Study of ADHD followup: Changes in effectiveness and growth after the end
of treatment. Pediatrics 113:762–769, 2004.
Pliszka SR, Matthews TL, Braslow KJ, Watson MA: Comparative effects of methylphenidate and mixed salts
amphetamine on height and weight in children with
attention-deficit/hyperactivity disorder. J Am Acad
Child Adolesc Psychiatry 45:520–526, 2006.
Poindexter A: Appetite suppressant drugs: A controlled
clinical comparison of benzphetamine, phenmetrazine,
d-amphetamine and placebo. Curr Ther Res Clin Exp
2:354–363, 1960.
Poulton A, Cowell CT: Slowing of growth in height and
weight on stimulants: A characteristic pattern. J Paediatr Child Health 39:180–185, 2003.
Safer D, Allen R, Barr E: Depression of growth in hyperactive children on stimulant drugs. N Engl J Med
287:217–220, 1972.
Satterfield JH, Cantwell DP, Schell A, Blaschke T: Growth
of hyperactive children treated with methylphenidate.
Arch Gen Psychiatry 36:212–217, 1979.

Schertz M, Adesman AR, Alfieri NE, Bienkowski RS: Predictors of weight loss in children with attention deficit
hyperactivity disorder treated with stimulant medication. Pediatrics 98:763–769, 1996.
Spencer TJ, Biederman J, Harding M, O’Donnell D,
Faraone SV, Wilens TE: Growth deficits in ADHD children revisited: Evidence for disorder-associated
growth delays? J Am Acad Child Adolesc Psychiatry
35:1460–1469, 1996.
Spencer TJ, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2
proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147, 2002.
Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J: Effects of atomoxetine on growth
after 2-year treatment among pediatric patients with
attention-deficit/hyperactivity disorder. Pediatrics
116:e74–e80, 2005.
Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper
KM, Zimmerman B, Concerta Study Group: Does prolonged therapy with a long-acting stimulant suppress
growth in children with ADHD? J Am Acad Child
Adolesc Psychiatry 45:527–537, 2006.
Sund AM, Zeiner P: Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 56:53–57, 2002.
Wang YC, Chong MY, Chou WJ, Yang JL: Prevalence of
attention deficit hyperactivity disorder in primary
school children in Taiwan. J Formos Med Assoc
92:133–138, 1993.
Wellman PJ: Norepinephrine and the control of food intake. Nutrition 16:837–842, 2000.
Wilens TE, Kratochvil C, Newcorn JH, Gao H: Do children and adolescents with ADHD respond differently
to atomoxetine? J Am Acad Child Adolesc Psychiatry
45:149–157, 2006.
World Medical Association: Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. As adopted
by the 18th World Medical Association General Assembly, Helsinki, Finland, June 1964 and amended by
the 52nd General Assembly, Edinburgh, Scotland, October 2000.
Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick
J: Effects of long-term psychostimulant medication on
growth of children with ADHD. Res Dev Disabil
27:162–174, 2006.

Address reprint requests to:
Dr. Thomas J. Spencer
Pediatric Psychopharmacology Clinic
Massachusetts General Hospital / Harvard
Medical School
55 Fruit Street
Boston, MA 02114-2696
E-mail: spencer@helix.mgh.harvard.edu.



    

                   !    "#$%
&'( )
 (  ( **# +   , '    -!   '!.     /    0    /      
1! #2$222&'( )
 1 ! (  # '  ( # '!  3 # , !  , !  # (  ,#   -# 4 . 
1 # 5 .  - # 3. (   # -  - # 6  ( #   '   1     
/   0   /  +    '  "7   -!   +  1  
 
   "8#2$2&.)&6  90 +4)&6  9-/6)&6  9-/6: 4 ;)
2 5 53 #<  (. #= -  # , ! #< . 1.#,   #! +, #+ 
/1  (! * #/ . 3 #-  .' - 1 >2? 3 %@2  : 
/0/    &'( )
$ 3   A #'  B -! -     /   0   /  
 
    "2#@2@$$&'( )
8 ,  , #, 54# ,* *0  + ! - +   1  5  
'      
    "2#CC%&'( )
C +6  ; # 0 !D#1  A6 #0 ;4 !    ! :  ! 
!9     /0/"  :           &'( )
% ''  #1 3 -!   /   0   /       "#
@$&'( )
@ -,* #/+3 #,<9!;#( #-+ !#,(, ; '  : . !!
  :           "   9       !   "#  "2#$8C
&'( )
 ,   00    4
#  (!!  #  B 3    E1       ! F E/    G
 ! . !    ! ! H  I     H    F $ % &'
&'( )
 -   * *# !1  #1  J#+;53#+  +<  #/   /  5 
!9       9    !      :           "%
!  ! . . #  .   (     ""1#2$$&'( )
 ,  00 4
# (!!  #B3   F0:  !   
 !           .  9  F     "%#$%2$@@&'( )
 = 1 0 #+ 0  4 !K ! : +     /   0   /  
)  "C#$@$$2&'( )
2 3   1A #1+#'  B       . !    !    
/0/*!       &'( )
$ ,!# 3 :; #3  #/' #+/; #(</ !#+/L #(0! #'0 #+
0 !#+0 ; <  #+4   9#5(  #( .  #-1#1  #51 !#51 
3; # 7 ' B <#  J # 0' 1   # 5    5        !       
!   /0/ + 
  "#CC&'( )
8 /  5+#'  B   /   0   /    "#$2&'( )
C B  - ,; # ,  + B    1   !9       /    0    /   
'    M)  "#%$%%&'( )
% (   -1 N '     ! !       #%&'( )
@ <J- @3   59 ( ; :    +    = O+.      
+,-./*  "2#$C$@&'( )
 B -,; #, +B  @!9        "#8&'( )
 4  # !1  # !53:#! 0 ;#B 1 #B1 #-   * *#/ <
< !#/  B  @K / !9      /   0   /    
   "#22$&'( )

 ' / #+;3#-  * *#4  #1  J#+  +<  #1 ,3 # !1  
@1   . !9   K 2=  '    < /0/  
  + 
  "#C8%$&'( )
 B   :. %-   1 ! "0 #< #'  +   '   -  
    + 
  "@#@CC@%&'( )
2 %'  :  "-!   !          )  "C# 9 &'( )

